CleaVR

Antibody Drug conjugates (ADCs) are the fastest growing therapeutic class of molecules, however, they are still plagued by unacceptable dose limiting toxicities predominantly due to excessive cytotoxicity of the associated payload. CleaVR aim to address this issue by developing a novel cytotoxic warhead platform which becomes inactive in non-tumour tissues. The aim is to collaborate with Bio-Pharma companies keen to develop ADCs.

BioCity invested in CleaVR because we know that the next generation of cytotoxics, with a better profile, is desperately needed.